EA200300046A1 - Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию - Google Patents
Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композициюInfo
- Publication number
- EA200300046A1 EA200300046A1 EA200300046A EA200300046A EA200300046A1 EA 200300046 A1 EA200300046 A1 EA 200300046A1 EA 200300046 A EA200300046 A EA 200300046A EA 200300046 A EA200300046 A EA 200300046A EA 200300046 A1 EA200300046 A1 EA 200300046A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- composition
- stomach
- volume
- retaining
- therapeutic agents
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 210000002784 stomach Anatomy 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 239000002552 dosage form Substances 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 229960001344 methylphenidate Drugs 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Manufacturing & Machinery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21383200P | 2000-06-23 | 2000-06-23 | |
| US21711000P | 2000-07-10 | 2000-07-10 | |
| US22321200P | 2000-08-04 | 2000-08-04 | |
| PCT/US2001/020134 WO2002000213A1 (en) | 2000-06-23 | 2001-06-22 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200300046A1 true EA200300046A1 (ru) | 2003-10-30 |
Family
ID=27395915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200300046A EA200300046A1 (ru) | 2000-06-23 | 2001-06-22 | Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1305021A4 (enExample) |
| JP (1) | JP2004501190A (enExample) |
| KR (1) | KR20030013460A (enExample) |
| AU (2) | AU2001268722B8 (enExample) |
| CA (1) | CA2412490A1 (enExample) |
| CZ (1) | CZ2003199A3 (enExample) |
| EA (1) | EA200300046A1 (enExample) |
| HU (1) | HUP0301465A3 (enExample) |
| IL (1) | IL153497A0 (enExample) |
| MX (1) | MXPA02012793A (enExample) |
| WO (1) | WO2002000213A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
| WO2003015745A1 (en) * | 2001-08-16 | 2003-02-27 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Expandable gastric retention device |
| BE1015608A6 (fr) | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
| US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| ATE347358T1 (de) * | 2003-04-17 | 2006-12-15 | Jallal Messadek | Schwimmende orale formulierungen mit kontrollierter freisetzung von betain |
| US20050113452A1 (en) * | 2003-10-20 | 2005-05-26 | Moshe Flashner-Barak | Composition and dosage form for sustained effect of levodopa |
| JP2005132803A (ja) * | 2003-10-31 | 2005-05-26 | Ono Pharmaceut Co Ltd | 胃内滞留固形剤 |
| TW200533391A (en) | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
| FR2874325B1 (fr) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
| WO2006050581A2 (en) | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
| EP2242489A1 (en) | 2005-02-15 | 2010-10-27 | Jallal Messadek | Combination therapeutic compositions and method of use |
| CN101180073A (zh) | 2005-04-27 | 2008-05-14 | 贾拉尔·梅萨德克 | 胰岛素组合 |
| NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| RU2484815C2 (ru) * | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| EP1872775A1 (en) | 2006-06-29 | 2008-01-02 | Polichem S.A. | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
| PE20080669A1 (es) * | 2006-09-08 | 2008-07-18 | Drugtech Corp | Composicion de liberacion sostenida que comprende levodopa |
| WO2008039186A2 (en) * | 2006-09-26 | 2008-04-03 | Plensat, Llc | Method and system for treatment of eating disorders |
| WO2008087882A1 (ja) | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | 胃内滞留型レボドパ徐放性製剤 |
| KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
| DE102007026037A1 (de) * | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Gastroretentives System mit Alginat-Körper |
| EP2192892A2 (en) * | 2007-07-27 | 2010-06-09 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
| US9320738B2 (en) | 2008-06-30 | 2016-04-26 | Tocagen Inc. | Formulations of 5-fluorocytosine and uses thereof |
| KR101687781B1 (ko) | 2008-08-15 | 2016-12-20 | 데포메드 인코퍼레이티드 | Ｃｎｓ 장애의 치료 및 예방을 위한 위 체류성 약학적 조성물 |
| CA2742680C (en) * | 2008-11-07 | 2013-12-31 | Samyang Corporation | Pharmaceutical compositions for release control of methylphenidate |
| EP2661262B1 (en) * | 2011-01-06 | 2017-11-15 | Mahmut Bilgic | Improved bisphosphonate formulations |
| CN103385871B (zh) * | 2012-05-07 | 2017-06-23 | 新疆医科大学 | 复方左旋多巴微囊漂浮片 |
| CN104334123B (zh) | 2012-06-07 | 2019-02-12 | 意比图密医疗有限公司 | 膨胀装置 |
| WO2014174388A1 (en) * | 2013-03-29 | 2014-10-30 | Wockhardt Limited | Modified release pharmaceutical compositions of methylphenidate or salts thereof |
| JP6204141B2 (ja) * | 2013-04-22 | 2017-09-27 | テイカ製薬株式会社 | 口腔内速崩壊性固形製剤用組成物 |
| US10994013B2 (en) | 2013-04-24 | 2021-05-04 | Temple University—Of the Commonwealth System of Higher Education | Solid dosage form containing arabinogalactan |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| PL3054929T3 (pl) | 2013-10-07 | 2021-05-31 | Impax Laboratories, Llc | Mukoadhezyjne preparaty lewodopy i / lub estrów lewodopy o kontrolowanym uwalnianiu oraz ich zastosowania |
| BR112016012615B1 (pt) | 2013-12-05 | 2023-02-07 | Epitomee Medical Ltd | Sistemas, e kit |
| JP2018506590A (ja) * | 2015-02-27 | 2018-03-08 | シンギュレイト・セラピューティクス・リミテッド・ライアビリティ・カンパニーＣｉｎｇｕｌａｔｅ Ｔｈｅｒａｐｅｕｔｉｃｓ ＬＬＣ | トリパルス放出型賦活薬製剤 |
| JP6823539B2 (ja) * | 2017-05-26 | 2021-02-03 | 株式会社ファンケル | 胃内滞留性錠剤 |
| DK3648747T3 (da) | 2017-06-16 | 2022-11-28 | Amneal Complex Products Res Llc | Gastroretentive doseringsformer til vedvarende frigivelse af lægemidler |
| US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
| US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
| WO2019246145A1 (en) | 2018-06-18 | 2019-12-26 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
| EP3970701B1 (en) | 2018-06-27 | 2025-05-07 | Amneal Complex Products Research LLC | Self-regulating osmotic gastroretentive drug delivery systems |
| JP7044649B2 (ja) * | 2018-06-28 | 2022-03-30 | 株式会社ファンケル | 胃内浮遊錠剤 |
| CA3139217A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| US20220241222A1 (en) * | 2019-06-26 | 2022-08-04 | Celista Pharmaceuticals Llc | Atomoxetine hydrochloride extended release compositions and methods of use |
| JP7624750B2 (ja) * | 2020-03-02 | 2025-01-31 | クラフト ヘルス プライベート リミテッド | 持続的薬物放出のための経口剤形 |
| KR20230124622A (ko) | 2020-12-22 | 2023-08-25 | 암닐 파마슈티컬스 엘엘씨 | 레보도파 투여 요법 |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| US11571402B2 (en) * | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| EP1003483A1 (en) * | 1997-07-23 | 2000-05-31 | Perio Products Ltd | Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
-
2001
- 2001-06-22 AU AU2001268722A patent/AU2001268722B8/en not_active Ceased
- 2001-06-22 IL IL15349701A patent/IL153497A0/xx unknown
- 2001-06-22 CZ CZ2003199A patent/CZ2003199A3/cs unknown
- 2001-06-22 KR KR1020027017538A patent/KR20030013460A/ko not_active Ceased
- 2001-06-22 EP EP01946709A patent/EP1305021A4/en not_active Withdrawn
- 2001-06-22 HU HU0301465A patent/HUP0301465A3/hu unknown
- 2001-06-22 JP JP2002504995A patent/JP2004501190A/ja active Pending
- 2001-06-22 MX MXPA02012793A patent/MXPA02012793A/es not_active Application Discontinuation
- 2001-06-22 AU AU6872201A patent/AU6872201A/xx active Pending
- 2001-06-22 EA EA200300046A patent/EA200300046A1/ru unknown
- 2001-06-22 CA CA002412490A patent/CA2412490A1/en not_active Abandoned
- 2001-06-22 WO PCT/US2001/020134 patent/WO2002000213A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL153497A0 (en) | 2003-07-06 |
| EP1305021A1 (en) | 2003-05-02 |
| HUP0301465A3 (en) | 2006-07-28 |
| HUP0301465A2 (hu) | 2004-05-28 |
| KR20030013460A (ko) | 2003-02-14 |
| AU6872201A (en) | 2002-01-08 |
| JP2004501190A (ja) | 2004-01-15 |
| AU2001268722B2 (en) | 2005-08-11 |
| MXPA02012793A (es) | 2004-07-30 |
| AU2001268722B8 (en) | 2005-09-29 |
| CA2412490A1 (en) | 2002-01-03 |
| WO2002000213A1 (en) | 2002-01-03 |
| CZ2003199A3 (cs) | 2003-12-17 |
| EP1305021A4 (en) | 2009-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02012793A (es) | Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion. | |
| EA200300045A1 (ru) | Композиция и лекарственная форма для задерживаемого желудочного выделения алендроната и/или других бис-фосфонатов | |
| BR9909903A (pt) | Eficácia máxima de substâncias usadas para melhorar a saúde e bem-estar | |
| BR0009016A (pt) | Composição de apomorfina e sildenafil | |
| EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
| DZ1884A1 (fr) | Formulations orales liquides d'alendronate. | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| DE60100595D1 (de) | Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson | |
| DE60100994D1 (de) | Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson | |
| IS7006A (is) | Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd | |
| JPH059412B2 (enExample) | ||
| MXPA05012810A (es) | Formas de dosis oral de memantina. | |
| PL370529A1 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug | |
| BG104797A (en) | Use of dexmedetomi dine for sedative effect in patients in an intensive care unit | |
| ATE543491T1 (de) | Kombinationspräparat enthaltend ibuprofen und paracetamol | |
| RU2002122084A (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| RU2002124141A (ru) | Применение миртазапина для лечения расстройств сна | |
| ATE446309T1 (de) | Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung | |
| BR0104586A (pt) | Método para tratamento de neurodegeneração | |
| TW200517119A (en) | Method of treatment using interferon-tau | |
| WO2005060939A3 (en) | Controlled-release pharmaceutical formulation | |
| MA28036A1 (fr) | Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil | |
| ATE454397T1 (de) | Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid | |
| RU2002129102A (ru) | Лечение разделенными дозами агентов с сосудоразрушающей активностью |